Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

06/02/2026, 1:00 PM • GlobeNewswire

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.

04/15/2026, 1:00 PM • GlobeNewswire

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Immunovant reported that its two Phase 3 clinical studies of batoclimab for thyroid eye disease (TED) failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24. However, safety results were consistent with previous findings with no new safety signals. The company remains focused on advancing IMVT-1402 in multiple autoimmune indications, with Graves' disease as a key priority and registrational study data expected in 2027.

04/02/2026, 5:00 AM • GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant reported Q3 2025 financial results with a net loss of $110.6 million. The company's IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis is fully enrolled with topline data expected in H2 2026. A $550 million financing was completed in December 2025, extending cash runway through potential Graves' disease launch. Development remains on track across multiple indications including GD, MG, CIDP, and SjD.

02/06/2026, 7:00 AM • GlobeNewswire

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?

Roivant Sciences purchased 16.7 million shares of Immunovant for $350 million, increasing its ownership to 64.65% of outstanding shares. The biotech company focuses on monoclonal antibody therapies for autoimmune diseases and is currently in clinical trials for its lead drug candidate.

12/18/2025, 2:35 AM • The Motley Fool

CENTURY ALUMINUM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Century Aluminum Co. - CENX

Law firm Kahn Swick & Foti, LLC has initiated an investigation into Century Aluminum Company, examining potential breaches of fiduciary duties or violations of state/federal laws by its officers and directors.

09/17/2025, 5:49 PM • GlobeNewswire

Why Immunovant Stock Blasted Higher Today

Immunovant's stock gained 11% after reporting positive results from a proof-of-concept study for batoclimab, an investigational drug targeting Grave's disease. The study showed 17 out of 21 patients maintained normal thyroid function six months after treatment.

09/03/2025, 6:17 PM • The Motley Fool

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Immunovant presented promising six-month off-treatment data for batoclimab in Graves' disease, showing ~80% of patients maintained normal thyroid function and ~50% achieved anti-thyroid drug-free remission.

09/03/2025, 12:57 PM • GlobeNewswire

Immunovant Posts 34% R&D Jump in Q1

Immunovant reported a widened net loss of $0.71 per share in Q1 FY2026, with increased research and development expenses of $101.2 million as the company advanced clinical trials for its lead anti-neonatal Fc receptor antibody IMVT-1402 across six different studies.

08/11/2025, 7:27 AM • The Motley Fool